StockData
BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc. (BBIO) stock

BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30
$78.17−1.37 (-1.72%)

Close on Nov 12, 2026Market cap $15.23BP/E –Yield –

BridgeBio Pharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

BridgeBio Pharma's ebitda for the twelve months ending Sep 30, 2026 was -$359.49M. For fiscal 2025 it was -$517.98M. The highest annual figure on record is -$265.38M in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$517.98M–
FY2024Dec 31, 2024-$586.90M–
FY2023Dec 31, 2023-$600.88M–
FY2022Dec 31, 2022-$505.43M–
FY2021Dec 31, 2021-$570.79M–
FY2020Dec 31, 2020-$473.03M–
FY2019Dec 31, 2019-$265.38M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$10.57M–
Q2 FY2026Jun 30, 2026-$106.03M–
Q1 FY2026Mar 31, 2026-$104.77M–
Q4 FY2025Dec 31, 2025-$138.13M–
Q3 FY2025Sep 30, 2025-$143.80M–
Q2 FY2025Jun 30, 2025-$132.96M–
Q1 FY2025Mar 31, 2025-$103.09M-5416.6%
Q4 FY2024Dec 31, 2024-$224.66M–
Q3 FY2024Sep 30, 2024-$190.21M–
Q2 FY2024Jun 30, 2024-$173.97M–
Q1 FY2024Mar 31, 2024$1.94M–
Q4 FY2023Dec 31, 2023-$175.83M–
Q3 FY2023Sep 30, 2023-$156.05M–
Q2 FY2023Jun 30, 2023-$144.46M–
Q1 FY2023Mar 31, 2023-$124.53M–
Q4 FY2022Dec 31, 2022-$127.57M–
Q3 FY2022Sep 30, 2022-$127.47M–
Q2 FY2022Jun 30, 2022-$78.59M–
Q1 FY2022Mar 31, 2022-$171.79M–
Q4 FY2021Dec 31, 2021-$164.09M–
Q3 FY2021Sep 30, 2021-$149.23M–
Q2 FY2021Jun 30, 2021-$90.53M–
Q1 FY2021Mar 31, 2021-$166.94M–
Q4 FY2020Dec 31, 2020-$127.05M–
Q3 FY2020Sep 30, 2020-$120.95M–
Q4 FY2019Dec 31, 2019-$78.40M–

More BridgeBio Pharma figures

See a number that looks wrong?